Who are CYB004's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clozaril, Risperdal Consta, Quetiapine and Topiramate, Intramuscular aripiprazole, olanzapine, Trazodone + PAP therapy, Risperidone, Haloperidol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyb004.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CYB004 — Competitive Intelligence Brief

CYB004 (CYB004) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin 5-HT2A receptor agonist. Area: Psychiatry.

phase 2 Serotonin 5-HT2A receptor agonist 5-HT2A Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

CYB004 (CYB004) — Cybin IRL Limited. CYB004 is a psychedelic compound that acts as a serotonin 5-HT2A receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CYB004 TARGET	CYB004	Cybin IRL Limited	phase 2	Serotonin 5-HT2A receptor agonist	5-HT2A
Clozaril	CLOZAPINE	Jazz Pharmaceuticals	marketed	Atypical Antipsychotic [EPC]	D2, 5-HT2A	1989-01-01
Risperdal Consta	Risperdal Consta	Zogenix, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Quetiapine and Topiramate	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Intramuscular aripiprazole, olanzapine	Intramuscular aripiprazole, olanzapine	Veterans Medical Research Foundation	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Trazodone + PAP therapy	Trazodone + PAP therapy	VA Office of Research and Development	marketed	Serotonin antagonist and reuptake inhibitor (SARI) + mechanical ventilation device	Serotonin transporter (SERT); serotonin 5-HT2A receptor antagonism
Risperidone, Haloperidol	Risperidone, Haloperidol	Ludwig-Maximilians - University of Munich	marketed	Antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-01 — Clozaril · 8057811 · Formulation · US

Sponsor landscape (Serotonin 5-HT2A receptor agonist class)

Cybin IRL Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CYB004 — Competitive Intelligence Brief. https://druglandscape.com/ci/cyb004. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab